In CRC, GABBR1-related research unveils a Hippo/YAP1 signaling pathway to demonstrate that GABBR1 inhibits the development of CRC and indirectly shows the feasibility of treatment targeting GABBR1 [72] (Figure 2). Here, YAP1 is linked to colorectal carcinoma.